Final Word on Avastin, and Why We Need Better Physicians

Today’s breaking breast cancer news is on Avastin. The FDA has just announced, formally, that it will rescind approval for the drug’s use in people with metastatic breast cancer. Commissioner Dr. Margaret Hamburg writes this her statement: I know I speak on behalf of the many physicians that have been involved with this issue here […]

Posted in Breast Cancer, cancer treatment, health care costs, Medical News, Oncology (cancer), PolicyTagged , , , , , , , , 1 Comment on Final Word on Avastin, and Why We Need Better Physicians

Patients’ Words, Unfiltered, Medical Journalism and Evidence

Yesterday’s post was not really about Avastin, but about medical journalism and how patients’ voices are handled by the media. L. Husten, writing on a Forbes blog, cried that the press fawned, inappropriately, over patients’ words at the FDA hearing last week, and that led him to wonder why and if journalists should pay attention to […]

Posted in Breast Cancer, cancer treatment, Empowered Patient, health care costs, Medical News, Oncology (cancer), PolicyTagged , , , , , , , , 2 Comments on Patients’ Words, Unfiltered, Medical Journalism and Evidence

Considering Evidence for a New Drug for Immune Thrombocytopenia Purpura

I’ve been wondering, lately, why so many of the medical blogs cover the same topics, like last week’s lung cancer detection trial, which are often the exact same studies as are reported by conventional news outlets. I’ve been trying, here, to sometimes consider new published articles that seem important to me but, for whatever reasons, don’t get so much attention.

Here’s one:

Yesterday’s NEJM includes an article Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia.* It’s about a drug, manufactured and sold by Amgen as NPlate, that received FDA approval for treatment of chronic immune thrombocytopenia purpura (ITP) in August, 2008. Some consider ITP a rare disease, and

Posted in Diagnosis, Hematology (blood), Under the RadarTagged , , , , , , Leave a Comment on Considering Evidence for a New Drug for Immune Thrombocytopenia Purpura

News, and Thoughts, on Comparative Effectiveness Research

What is comparative effectiveness research and why does it matter? The idea, basically, is to inform medical decisions with relevant data derived from well-designed clinical trials. This sort of research will provide the foundation for evidence-based medicine (EBM).

Posted in Future of Medicine, health care costs, health care delivery, Medical Ethics, Policy, Public HealthTagged , , , Leave a Comment on News, and Thoughts, on Comparative Effectiveness Research

More News, and Considerations, on OncotypeDx

This week I’ve been reading about new developments in breast cancer (BC) pathology. At one level, progress is remarkable. In the 20 years since I began my oncology fellowship, BC science has advanced to the point that doctors can distinguish among cancer subtypes and, in principle, stratify cases according to patterns of genes expressed within […]

Posted in Breast Cancer, cancer treatment, clinical trials, Diagnosis, Informed Consent, Oncology (cancer), Pathology, Patient AutonomyTagged , , , , , , , , , Leave a Comment on More News, and Considerations, on OncotypeDx
newsletter software